HDT Bio

About

HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.

Seattle,Washington,United States
11 - 50
https://www.hdt.bio

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: $49M
Industries: Biopharma,Biotechnology,Pharmaceutical
Founded date: Jan 1, 2018
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: HDT Bio Corp.

HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission is to maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

$67.95M

HDT Bio has raised a total of $67.95M in funding over 2 rounds. Their latest funding was raised on Nov 30, 2022 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 30, 2022	Grant	$49M	1	Medical CBRN Defense Consortium	—	Detail
Aug 8, 2022	Grant	$1.80M	1	US Army	—	Detail
May 17, 2021	Grant	$2.90M	1	National Institutes of Health	—	Detail
Oct 5, 2020	Seed	$6M	2	Zoic Capital	—	Detail
Sep 1, 2020	Grant	$8.25M	1	National Institute of Allergy and Infectious Diseases	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

6

HDT Bio is funded by 6 investors. Medical CBRN Defense Consortium and US Army are the most recent investors.

Investor Name	Lead Investor	Funding Round
Medical CBRN Defense Consortium	Yes	Grant
US Army	Yes	Grant
National Institutes of Health	Yes	Grant
Zoic Capital	Yes	Seed
National Institute of Allergy and Infectious Diseases	Yes	Grant
Eric Anschutz	—	Seed